A Comparison of XELOX Regimen and EOX Regimen as Neoadjuvant Chemotherapy Regimen for Locally Advanced Gastric Cancer.
Launched by TIANSHU LIU · Jul 16, 2014
Trial Information
Current as of July 09, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • more than 2 regional bulky lymph nodes macroscopic tumor type is either the Borrmann type 4 or large type 3 tumor invades adjacent structures (T4b)
- Exclusion Criteria:
- • peritoneal metastasis confirmed by CT scan lung metastasis, liver metastasis, pleural effusion, and/or other distant metastasis
About Tianshu Liu
Tianshu Liu is a dedicated clinical trial sponsor specializing in the development and management of innovative research initiatives aimed at advancing medical science and improving patient outcomes. With a robust portfolio that encompasses various therapeutic areas, Tianshu Liu emphasizes rigorous scientific methodologies and ethical standards in conducting clinical trials. The organization is committed to fostering collaboration among researchers, healthcare professionals, and regulatory bodies to ensure the successful implementation of trials that adhere to the highest quality and compliance benchmarks. Through its strategic approach, Tianshu Liu aims to contribute significantly to the advancement of healthcare solutions and the overall well-being of patients globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Patients applied
Trial Officials
tianshu liu
Study Chair
Shanghai Zhongshan Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials